Evidence map›Paper›PMID 24778283›Full record

SynthesisNeurology2014

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Barbara S Koppel, John C M Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, Gary Gronseth, David Gloss

4 registry-linked trialsOpen access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 191 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 9 pooled it
58.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03639064 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease

TypeinterventionalSponsorUniversity Health Network, TorontoRan2020 to 2022Enrolled15ConditionsParkinson DiseaseArmsCannabis Oil
NCT03994640 phase2 / phase3completednot on this mapstarted 2018, after this paper: background citation

Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study

TypeinterventionalSponsorMedical University of SilesiaRan2018 to 2019Enrolled20ConditionsTemporomandibular Disorder, Myofascial Pain, Cannabis, ElectromyographyArmsCannabis Cream, Placebo Cream
NCT04406948 phase2withdrawnnot on this mapstarted 2024, after this paper: background citation

Randomized, Double Blind, Placebo Controlled, Parallel Design Phase II b Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

TypeinterventionalSponsorMGC Pharmaceuticals d.o.oRan2024 to 2024Enrolled0ConditionsResistant Epilepsy, Drug, Adolescent Epilepsy, Children Epilepsy, Children and Adolescents With Resistant EpilepsiesArmsMGCND00EP1, Placebo, ECG, EEG, Blood and urine collection
NCT04775030 phase2 / phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Methodology for Developing an Occlusal Appliance With CBD Active Carrier

TypeinterventionalSponsorMedical University of SilesiaRan2021 to 2023Enrolled40ConditionsTemporomandibular Disorder, Myofascial Pain, Cannabis, ElectromyographyArmsCBD occlusal appliance, Acrylic resin occlusal appliance
3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 9 syntheses or guidelines pooled it, 543 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cannabis-based medicines for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Cannabinoids in Pain Management and Palliative Medicine.Deutsches Arzteblatt international · 2017
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015
    Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.European archives of psychiatry and clinical neuroscience · 2025
    Review

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Barbara S KoppelFrom the Department of Neurology (B.S.K.), New York Medical College, New York; the Department of Neurology (J.C.M.B.), Columbia University College of Physicians & Surgeons, New York Neurological Institute, New York; University of Arizona College of Medicine (T.F.), Phoenix; the Department of Neurology (J.B.), David Geffen School of Medicine at University of California Los Angeles, The VA Greater Los Angeles Healthcare System; the Department of Neurology (S.Y.), University of New Mexico Health Sciences Center, Albuquerque; the Department of Neurology (G.G.), University of Kansas School of Medicine, Kansas City; and the Department of Neurology (D.G.), Geisinger Health System, Danville, PA.
John C M Brust
Terry Fife
Jeff Bronstein
Sarah Youssof
Gary Gronseth
David Gloss
New York College of Health Professions · USNew York Medical College · USUniversity of Arizona · USUniversity of Kansas · USUniversity of New Mexico · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the efficacy of medical marijuana in several neurologic conditions.

methodsWe performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles.

resultsThirty-four studies met inclusion criteria; 8 were rated as Class I.

conclusionsThe following were studied in patients with MS: (1) Spasticity: oral cannabis extract (OCE) is effective, and nabiximols and tetrahydrocannabinol (THC) are probably effective, for reducing patient-centered measures; it is possible both OCE and THC are effective for reducing both patient-centered and objective measures at 1 year. (2) Central pain or painful spasms (including spasticity-related pain, excluding neuropathic pain): OCE is effective; THC and nabiximols are probably effective. (3) Urinary dysfunction: nabiximols is probably effective for reducing bladder voids/day; THC and OCE are probably ineffective for reducing bladder complaints. (4) Tremor: THC and OCE are probably ineffective; nabiximols is possibly ineffective. (5) Other neurologic conditions: OCE is probably ineffective for treating levodopa-induced dyskinesias in patients with Parkinson disease. Oral cannabinoids are of unknown efficacy in non-chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy. The risks and benefits of medical marijuana should be weighed carefully. Risk of serious adverse psychopathologic effects was nearly 1%. Comparative effectiveness of medical marijuana vs other therapies is unknown for these indications.

Indexed as

Guidelines as TopicAcademies and InstitutesHumansMedical MarijuanaNervous System DiseasesRetrospective StudiesUnited StatesMedical Marijuana

Identifiers

PMID24778283
PMCPMC4011465
OpenAlexW2096621017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.